AtaiBeckley Inc.
ATAIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The $1.62B market capitalization puts ATAI squarely in small-cap range for its industry. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder.
Market Cap
$1.62B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-9.69
EPS (TTM)
$-2.84
EPS (Fwd)
$-0.46
ROE
-378.0%
ROA
-33.0%
Cash
$230.8M
Total Debt
$2.0M
Free CF
—
52W Change
90.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $230.8M in cash comfortably exceeding the $2.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Return on equity stands at -378.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $233K (2022) to $4.1M (2025), reflecting a 1655% increase over the period.
With cash comfortably exceeding debt, ATAI has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AtaiBeckley Inc. and its sector.